- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Oral Acitretin and TAC Effective in treatment of Oral Lichen Planus: JAMA
Symptomatic Oral Lichen Planus (OLP) has been a formidable challenge to treat, but a recent clinical trial revealed a positive outcome. The study from Postgraduate Institute of Medical Education and Research in Chandigarh, compared the efficacy of a combination therapy of oral acitretin with topical triamcinolone acetonide (TAC) and 0.1%—with TAC monotherapy in patients with symptomatic OLP. The findings of the study were published in Journal of American Medical Association.
This investigator-initiated trial involved 64 patients aged 18 and older with symptomatic OLP, employing a placebo-controlled, investigator- and patient-blinded randomized design. The patients were randomized into a group receiving a combination of oral acitretin and TAC, and the other group receiving TAC combined with a placebo. The treatment was for 28 weeks with an additional 8 weeks of treatment-free follow-up.
Results showed a statistically significant advantage for the combination therapy. In the intention-to-treat analysis, a higher number of patients in the treatment group achieved a 75% or higher reduction in Oral Disease Severity Score (ODSS) compared to the placebo group at both 28 weeks and 36 weeks.
The combination therapy demonstrated a superior performance in the reduction of relapses during the posttreatment follow-up. The low relapse rates further solidified the effectiveness of the dual approach, offering a ray of hope for patients suffering with symptomatic OLP.
This trial opened new doors for managing OLP, indicating that a combination of oral acitretin and TAC might be a potent therapeutic strategy than TAC monotherapy. The medical community anticipates the treatment landscape for symptomatic OLP by improving the quality of life for many individuals affected by this challenging condition.
Source:
Vinay, K., Kumar, S., Dev, A., Cazzaniga, S., Borradori, L., Thakur, V., & Dogra, S. (2023). Oral Acitretin Plus Topical Triamcinolone vs Topical Triamcinolone Monotherapy in Patients With Symptomatic Oral Lichen Planus. In JAMA Dermatology. American Medical Association (AMA). https://doi.org/10.1001/jamadermatol.2023.4889
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751